NR1H3 and myeloid sarcoma: In addition, Wang et al. have found an LXRα mutation, in two multi-incident families presenting with severe and progressive MS disease, that disrupts LXRα heterodimerisation and transcriptional activation of target genes, further linking LXR and its agonists with MS pathogenesis [39].